Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2013 1
2014 1
2015 2
2016 1
2017 1
2018 1
2019 1
2020 3
2021 3
2022 5
2023 2
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, LoRusso PM, Alonso G, Rodriguez-Ruiz ME, Schoedel KB, Blum JM, Sänger B, Salcedo TW, Burm SM, Stanganello E, Verzijl D, Vascotto F, Sette A, Quinkhardt J, Plantinga TS, Toker A, van den Brink EN, Fereshteh M, Diken M, Satijn D, Kreiter S, Breij ECW, Bajaj G, Lagkadinou E, Sasser K, Türeci Ö, Forssmann U, Ahmadi T, Şahin U, Jure-Kunkel M, Melero I. Muik A, et al. Among authors: sasser k. Cancer Discov. 2022 May 2;12(5):1248-1265. doi: 10.1158/2159-8290.CD-21-1345. Cancer Discov. 2022. PMID: 35176764 Free PMC article. Clinical Trial.
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Muik A, Adams 3rd HC, Gieseke F, Altintas I, Schoedel KB, Blum JM, Sänger B, Burm SM, Stanganello E, Verzijl D, Spires VM, Vascotto F, Toker A, Quinkhardt J, Fereshteh M, Diken M, Satijn DPE, Kreiter S, Ahmadi T, Breij ECW, Türeci Ö, Sasser K, Sahin U, Jure-Kunkel M. Muik A, et al. Among authors: sasser k. J Immunother Cancer. 2022 Jun;10(6):e004322. doi: 10.1136/jitc-2021-004322. J Immunother Cancer. 2022. PMID: 35688554 Free PMC article.
Destabilized host-parasite dynamics in newly founded populations.
Bolnick DI, Barrett RDH, Choi E, Eckert L, Hendry AP, Kerns EV, Lind ÅJ, Milligan-McClellan K, Peichel CL, Sasser K, Thornton AR, Wolf C, Steinel NC, Weber JN. Bolnick DI, et al. Among authors: sasser k. bioRxiv [Preprint]. 2024 Jun 27:2024.06.24.600494. doi: 10.1101/2024.06.24.600494. bioRxiv. 2024. PMID: 38979317 Free PMC article. Preprint.
Could daratumumab be used to treat severe allergy?
Blankestijn MA, van de Donk NWCJ, Sasser K, Knulst AC, Otten HG. Blankestijn MA, et al. Among authors: sasser k. J Allergy Clin Immunol. 2017 May;139(5):1677-1678.e3. doi: 10.1016/j.jaci.2016.12.955. Epub 2017 Jan 19. J Allergy Clin Immunol. 2017. PMID: 28109726 No abstract available.
Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non-Small Cell Lung Cancer.
Owen D, Ben-Shachar R, Feliciano J, Gai L, Beauchamp KA, Rivers Z, Hockenberry AJ, Harrison G, Guittar J, Catela C, Parsons J, Cohen E, Sasser K, Nimeiri H, Guinney J, Patel J, Morgensztern D. Owen D, et al. Among authors: sasser k. JAMA Netw Open. 2024 Nov 4;7(11):e2442970. doi: 10.1001/jamanetworkopen.2024.42970. JAMA Netw Open. 2024. PMID: 39495511 Free PMC article.
23 results